Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
10/2007
10/31/2007CN100345842C Dimeric compounds and their use as anti-viral agents
10/31/2007CN100345773C Biofilm carrier with improved specific surfacial area,bio-affinity and flowability
10/31/2007CN100345594C Acetazolamide eye droplet and its application method in treating glaucoma
10/31/2007CN100345592C Mono and disaccharide derivatives
10/31/2007CN100345549C Method of administration of bisphosphonates by inhalation in the treatment or prevention of bone resorption and osteoporosis
10/31/2007CN100345541C Microcapsules for the delayed, controlled release of perindopril
10/31/2007CN100345535C The Controlled release preparation of insulin and its method
10/31/2007CN100345532C Process for dispersing a fluid in solid particles
10/31/2007CN100345528C Insert for the treatment of dry eye
10/30/2007US7288534 Sphingomyelin enhancement of tumor therapy
10/30/2007US7288527 Inhibition of allergic contact dermatitis by N-L-alpha-aspartyl-L-phenylalanine 1-methyl ester
10/30/2007US7288280 Complete feed for fish larvae and method for preparing same
10/30/2007US7288267 Bioadhesive nanoparticulate compositions having cationic surface stabilizers
10/30/2007US7288262 Composition comprising a cyclohexane-based compound, compound and use of said compound to structure a composition
10/30/2007US7288254 Use of immunotoxins to induce immune tolerance to pancreatic islet transplantation
10/30/2007US7288248 Antibodies against cancer antigen TMEFF2 and uses thereof
10/30/2007US7288247 Binding antibody to epitopes
10/30/2007US7288243 Aerosol drug inhibition of lung metastases
10/30/2007CA2451433C Oligopeptide transporter 1 inhibitor
10/30/2007CA2329232C Stable compositions comprising levosimendan and alginic acid
10/30/2007CA2328703C Delavirdine tablet formulation
10/30/2007CA2288948C Modified arginine deiminase
10/30/2007CA2257552C Use of carotenoid aggregates as colorants
10/30/2007CA2219991C Taste masking pharmaceutical composition for oral administration
10/30/2007CA2186760C Use of biopolymers for the muscle treatment
10/30/2007CA2183577C Methods and compositions for pulmonary delivery of insulin
10/30/2007CA2171218C Metallospheres and superclusters
10/30/2007CA2145397C Group b streptococcus type ii and type v polysaccharide-protein conjugate vaccines
10/30/2007CA2105101C The use of the il-4 receptor for the therapy, prophylaxis and diagnosis of allergic, viral, parasitic and bacterial diseases and of fungal infections
10/26/2007WO2007127630A1 Controlled released preparations of oxcarbazepine having sigmoidal release profile
10/25/2007WO2007120693A2 Targeted binding agents directed to upar and uses thereof
10/25/2007WO2007120556A2 Antiviral methods
10/25/2007WO2007120479A1 Biodegradable cationic polymers
10/25/2007WO2007119792A1 Dry direct compression fast disintegrating tablet
10/25/2007WO2007119741A1 Novel sweetener
10/25/2007WO2007119724A1 Drug delivery particle and method for production thereof
10/25/2007WO2007119684A1 Spraying agent
10/25/2007WO2007119656A1 Tamsulosin-containing percutaneous absorption type preparation
10/25/2007WO2007119467A1 Percutaneous absorption promoting agent and percutaneous absorption preparation using the same
10/25/2007WO2007119185A2 Degradable therapeutic delivery device
10/25/2007WO2007118802A1 Aerosol suspension formulations comprising tg 227 ea or tg 134 a as propellants
10/25/2007WO2007118631A1 Phospholipid complexes of olive fruits or leaves extracts having improved bioavailability
10/25/2007WO2007098591A3 Topical nail formulation
10/25/2007WO2007091250A8 Enzyme replacement therapy for treating lysosomal storage diseases
10/25/2007WO2007063300A3 Particles
10/25/2007WO2007056205A3 Carboxyalkylcellulose esters for administration of poorly soluble pharmaceutically active agents
10/25/2007WO2007056153B1 Peptide-dicer substrate rna conjugates as delivery vehicles for sirna
10/25/2007WO2007037886A3 Methods for treatment and prevention of otitis media using nonionic surfactants to facilitate transmembrane drug delivery into the middle ear
10/25/2007WO2007035942A3 Transdermal risperidone delivery system
10/25/2007WO2007011940A3 Sustained release of antiinfectives
10/25/2007WO2006138735A3 Gel compositions for topical administration
10/25/2007WO2005034877A3 G-csf transferrin fusion proteins
10/25/2007WO2002048116A3 Inhibitors of hepatitis c virus ns3 protease
10/25/2007US20070250600 System and method for queuing data for an application server
10/25/2007US20070249735 Halide-free glucosamine-acidic drug complexes
10/25/2007US20070249734 Method, Composition and Kit for Detecting Phosphatidylserine (Ps) on Cell Membranes
10/25/2007US20070249692 Inhibitors of crystallization in a solid dispersion
10/25/2007US20070249671 Pharmaceutical composition for piperidinoalkanol compounds
10/25/2007US20070249576 Cefdinir Oral Suspension
10/25/2007US20070249564 Novel phosphorus-containing prodrugs
10/25/2007US20070249551 Compositions and methods for non-parenteral delivery of oligonucleotides
10/25/2007US20070249537 Absorption enhancing agents
10/25/2007US20070249522 Injectable formulations containing succinate
10/25/2007US20070249033 Methods of terminal sterilization of biological products
10/25/2007US20070248972 Page-4, an X-linked gage-like gene expressed in normal and neoplastic prostate, testis and uterus, and uses therefor
10/25/2007US20070248697 Opthalmic solutions
10/25/2007US20070248686 Colloidal suspension of submicronic particles as vectors for active principles and method for preparing same
10/25/2007US20070248676 Use of nitric oxide adducts
10/25/2007US20070248674 Hydrogel Interferon Formulations
10/25/2007US20070248663 Utilization of Dialkylfumerates
10/25/2007US20070248662 Immunosuppressants; for use in transplantation medicine or treatment of autoimmune diseases such as polyarthritis but not psoriatitc arthritis; micro-tablets, pellets
10/25/2007US20070248652 Nutritional Food and Feed, Compostition, Processing and Method of Use
10/25/2007US20070248650 Food Products Comprising Long Chain Polyunsaturated Fatty Acids and Methods for Preparing the Same
10/25/2007US20070248649 Of soluble and insoluble carbohydrates for dietetics and pharmaceuticals to promote the flora of the large intestine, lactic acid bacteria, and in infant formulas; probiotics
10/25/2007US20070248648 High protein, fatigue reducing powder
10/25/2007US20070248647 Erythritol suppression of ghrelin
10/25/2007US20070248642 Foam and use thereof
10/25/2007US20070248626 Recombinant toxin fragments
10/25/2007US20070248617 Medical Uses of Carrier Conjugates of Non-Human Tnf -Peptides
10/25/2007US20070248577 Methods and compositions for administering stem cells
10/25/2007US20070248571 Ejection Liquid, Ejection Method, Method for Forming Liquid Droplets, Liquid Ejection Cartridge and Ejection Apparatus
10/25/2007US20070248569 Eye-Drop Vaccine Containing Copolymer 1 for Therapeutic Immunization
10/25/2007US20070248565 Pharmaceutical preparations comprising corticosteroids and antiinfective agents
10/25/2007US20070248545 Use of the receptor GPR86
10/25/2007US20070248541 Liposome
10/25/2007CA2683664A1 Compositions comprising pyruvate alkyl esters and uses thereof
10/25/2007CA2649431A1 N protein fusion proteins of a virus in the paramyxoviridae-protein of interest family and their use for intracellular vectorization and vaccination
10/25/2007CA2649360A1 Mono and di-substituted oxycodone compounds and compositions
10/25/2007CA2649326A1 Targeted binding agents directed to upar and uses thereof
10/25/2007CA2649149A1 Nanoparticle containing nicotine and/or cotinine, dispersions, and use thereof
10/25/2007CA2649114A1 Compositions and methods for modulating gene expression
10/25/2007CA2648982A1 Aerosol suspension formulations comprising tg 227 ea or tg 134 a as propellants
10/25/2007CA2648958A1 Phospholipid complexes of olive fruits or leaves extracts having improved bioavailability
10/25/2007CA2648950A1 Composition including at least one aqueous phase and at least one fatty phase including ivermectin
10/25/2007CA2648386A1 Biodegradable cationic polymers
10/25/2007CA2646503A1 Dialkyl ether delivery agents
10/25/2007CA2643728A1 Pharmaceutical composition containing sympathomimetic amine salt and co-distillable additive
10/24/2007EP1847614A1 Compositions for delivering enzymes involved in amino acid metabolism using recombinant adeno-associated virus virions (raav virions), and method and use for treating amino acid metabolic disorders using such raav virions
10/24/2007EP1847550A2 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
10/24/2007EP1847271A2 Water-absorbent polymers and their use as a medicament
1 ... 718 719 720 721 722 723 724 725 726 727 728 729 730 731 732 733 734 735 736 737 738 ... 1712